Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amicus Therapeutics, Inc. - Common Stock (NQ:FOLD)

9.800 -0.130 (-1.31%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,362,260
Open 9.920
Bid (Size) 9.810 (500)
Ask (Size) 10.03 (500)
Prev. Close 9.930
Today's Range 9.770 - 10.05
52wk Range 5.510 - 10.57
Shares Outstanding 266,555,274
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Q3 2025 Earnings: A Landmark Quarter with Strong Profitability Beat ↗
Amicus Therapeutics (FOLD) beats Q3 2025 earnings estimates with strong revenue growth and a major milestone in profitability, driving positive market momentum. 
Via Chartmill
News headline image
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+5.3%
+5.3%
1 Month
+8.5%
+8.5%
3 Month
+24.4%
+24.4%
6 Month
+59.1%
+59.1%
1 Year
-1.6%
-1.6%

More News

Read More
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For July 31, 2025 ↗
Via Benzinga
News headline image
Earnings Scheduled For May 1, 2025 ↗
Via Benzinga
News headline image
Amicus Therapeutics Earnings Preview ↗
Via Benzinga
News headline image
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday ↗
Via Benzinga
News headline image
New 4-Year Data for Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Presented at ICIEM
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via Investor Brand Network
Topics Government
News headline image
Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators
Via FinancialNewsMedia
Topics Government
News headline image
Amicus (FOLD) Q2 Revenue Jumps 22% ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Amicus Therapeutics Inc (NASDAQ:FOLD) Beats Q2 2025 Earnings and Revenue Estimates, Shares Rise in Pre-Market Trading ↗
Via Chartmill
News headline image
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce Second Quarter 2025 Financial Results on July 31, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics Announces Approval of Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) in Japan
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Amicus Therapeutics to Present at the Bank of America 2025 Health Care Conference
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
Amicus Therapeutics Announces First Quarter 2025 Financial Results and Corporate Updates
From Amicus Therapeutics, Inc.
Via GlobeNewswire
News headline image
Dimerix and Amicus Therapeutics Announce Exclusive License Agreement for DMX-200 in the United States
From Amicus Therapeutics, Inc.; Dimerix Limited
Via GlobeNewswire
News headline image
Amicus Therapeutics to Announce First Quarter 2025 Financial Results on May 1, 2025
From Amicus Therapeutics, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Amicus Therapeutics, Inc. - Common Stock publicly traded?
Yes, Amicus Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Amicus Therapeutics, Inc. - Common Stock trade on?
Amicus Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Amicus Therapeutics, Inc. - Common Stock?
The ticker symbol for Amicus Therapeutics, Inc. - Common Stock is FOLD on the Nasdaq Stock Market
What is the current price of Amicus Therapeutics, Inc. - Common Stock?
The current price of Amicus Therapeutics, Inc. - Common Stock is 9.800
When was Amicus Therapeutics, Inc. - Common Stock last traded?
The last trade of Amicus Therapeutics, Inc. - Common Stock was at 12/01/25 04:00 PM ET
What is the market capitalization of Amicus Therapeutics, Inc. - Common Stock?
The market capitalization of Amicus Therapeutics, Inc. - Common Stock is 2.61B
How many shares of Amicus Therapeutics, Inc. - Common Stock are outstanding?
Amicus Therapeutics, Inc. - Common Stock has 3B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.